Novartis India Ltd.

1961
 
 - The Company was incorporated on 5th January.  The Company was
 registered on 13th December, 1947 under the name Ciba Pharma Pvt.
 Ltd., as a wholly owned subsidiary of Ciba Ltd., Basle, Switzerland
 to
 take over the trading business in pharmaceuticals from the parent
 company's another Indian subsidiary, viz., Ciba (India) Ltd., the
 name
 of which was changed later to Ciba Dyes Pvt. Ltd., with effect from
 1st
 March, 1948.  Ciba Dyes Pvt.  Ltd., was registered in India on 13th
 June, 1928 and was dealing in dyestuffs and pharmaceuticals.
 
 - The name of the Company was changed from Ciba Pharma Pvt. Ltd., to
 Ciba of India Ltd., with effect from 5th January, soon after the
 amalgamation of Ciba Dyes Pvt. Ltd., with the Company with effect
 from
 31st December, 1960.
 
 - The name of the Company was again changed to Ciba-Geigy of India
 Ltd., with effect from 21st October, 1970.  With effect from 1st
 January, 1983, the name of the Company was changed from Ciba-Geigy
 of
 India Ltd., to Hindustan Ciba-Geigy Ltd., to reflect the forthcoming
 change in its status to that of Indian company on eventual reduction
 of
 the foreign equity of 40%.
 
 - From purely trading activities, the Company moved to the
 manufacture
 of pharmaceutical formulations.  Then it undertook the manufacture of
 a
 large number of bulk drugs, many invovling both high technology and
 basic manufacture.
 
 - The Company also diversified its activities by undertaking the
 basic
 manufacture of pesticides in a backward region in Goa.  It also
 entered
 the export field by establishing a 100% export unit in Kandla Free
 Trade Zone.
 
 - Technical know-how for the manufacture of organic phosphates &
 Phospites and textile auxiliaries of the Company which would be
 implemented in the near future was being supplied to the Company
 free
 of all charge by Ciba-Geigy, Basle, Switzerland.
 
 - The Company holds a letter of intent for the manufacture of EPN
 resins and submitted an application to the Government of India,
 seeking
 approval for foreign collaboration for the project with Ciba-Geigy,
 Basle, Switzerland.
 
 - The majority of products marketed by the Company bear trade marks
 which are covered by Licensed User Agreements dated 14th October,
 1971
 (As modified by the Agreement dated 14th August, 1974), 5th
 February,
 1975, 29th March, 1978, 5th March, 1981, 12th August, 1982 and 17th
 March, 1983 concluded between the Company and Ciba-Geigy, Basle,
 Switzerland.
 
 1965
 
 - 25,000 rights equity shares issued at par in proportion 1:2 on 9th
 July.
 
 1966
 
 - 2,50,000 bonus equity shares issued in proportion 10:3 on 17th
 October.
 
 1971
 
 - Pesticides are manufactured at the Company's plant at Santa
 Monica,
 Goa.  The pesticides manufactured by the Company are used for the
 control of pests affecting cotton, rice, oilseeds, pulses,
 vegetables,
 fruit crops, etc.  The Company's marketing efforts are buttressed by
 the extension of services which it provides to the agriculturist.
 
 - 1,62,500 bonus shares issued in proportion 1:2 on 18th October.
 
 - Out of the total shares issued till December 1971, 3,16,875 shares
 held by CIBA-GEIGY, Ltd. Basle, Switzerland.
 
 - Consumer products were manufactured by the Company at its Bhandup
 plant.  It also markets toothbrushes.  Consumer products of the
 Company
 are being marketed under the brand name BINACA.
 
 1975
 
 - 1,30,000 Bonus shares issued in prop. 4:15 on 16.6.1975.
 
 1977
 
 - 3,08,750 bonus shares issued in prop. 1:2 on 14.11.1977.
 
 1980
 
 - 4,63,125 bonus shares issued in prop. 1:2 on 9.10.1980.
 
 1982
 
 - The Company entered into an Agreement dated 11th March, with
 Ciba-Geigy, Basle, Switzerland.
 
 1983
 
 - Ciba-Geigy, Ltd., Switzerland was permitted by the Reserve Bank of
 India to disinvest 1,94,783 equity shares of Rs 100 each at a
 premium
 of Rs. 75 per share in favour of the existing resident Indian equity
 shareholders.  Accordingly, offers were made to the resident equity
 shareholders in terms of a letter dated 12th February, 1985.
 
 - The object of the public issue of equity capital during July, was
 to
 dilute the foreign equity from 65% to 51%.  The proceeds of the
 issue
 were being utilised to finance the Company's ongoing and future
 projects.
 
 - 3,81,400 shares issued at a prem. of Rs 40 per share through a
 prospectus out of which the following shares were reserved and
 allotted: 28,330 shares to employees and working directors of the
 Company; 7,080 shares for business associates of the Company and
 27,250
 shares to financial institutions (in equal prop. to LIC, GIC and
 UTI).
 The balance 3,18,740 shares offered for public subscription during
 July/August.
 
 1985
 
 - The Company was permitted by Ciba Geigy, Ltd., Switzerland to use
 their trade mark `CIBACA' for the consumers products marketed by the
 Company.  The trade mark BINACA were permitted to be used for a
 transitional period upto the end of 1986.
 
 - The epoxy resins marketed by the Company under the brand name of
 Araldite are required for a host of critical industrial applications
 ranging from anti-corrosion to India's aerospace programme.
 
 1988
 
 - A new fomulation voveran SR - Sutained Release were successfully
 launched.  New products, like Ridomil M272 WP for the control of
 diseases affecting grapes and tobacco and Fasinex for the control of
 flukes in cattle and sheep were introduced.
 
 - A letter of intent for the manufacture of 700 tonnes per annum of
 saturated polyester resins for powder coatings were received.
 
 1989
 
 - A letter of intent was received for the manufacture of 1200 tons
 p.a.
 of speciality chemicals for the detergents, dyes and textile
 industries.  An agreement was reached with UCB S.A., Belgium, to
 manufacture saturated polyester resins locally.
 
 - Another letter of intent was received for the manufacture of
 anti-oxidants with the technical know-how to be provided by
 CIBA-GEIGY
 of Switzerland.  The plant facilities at the agricultural chemicals
 division were being modernised.
 
 1990
 
 - The dyes and chemicals division consolidated its position in the
 field of leather chemicals with additional products in synthetic
 tanning agents and dyestuffs.
 
 - The letter of Intent for the manufacture of saturated polyester
 resins was converted into an industrial licence.  A new plant for
 the
 manufacture of saturated polyester resins was proposed to be
 implemented shortly in technical collaboration with UCB, SA,
 Belgium.
 
 - The Company made an offer to Citibank, NA, Mumbai for private
 placement of 10,00,000-14% non-convertible debentures of Rs. 100
 each.
 The debentures would be redeemed at a premium of 5% in three equal
 instalments after expiry of 6th, 7th and 8th years from the date of
 allotment of the debentures.
 
 - 8,85,387 bonus shares issued in prop. 1:2.
 
 1991
 
 - The sales of consumer health care unit was affected due to the
 chloride controversy.  During the year, the Cibaca lime gel tooth
 paste
 was test marketed.  The agricultural division launched during
 December,
 APRON 35 WS, a seed dressing fungicide for control of the diseases
 in
 bajra, sorghum, rapeseed etc.
 
 - The saturated polyester resin unit in Goa was commissioned.
 
 - The Company re-assesed the anti-oxidants project at Goa both from
 the
 point of view of the devaluation of Rupee and the new import policy
 which had affected the business conditions to a large extent.
 
 - The Company, issued 15.5% secured non-convertible debentures
 aggregating Rs. 1000 lakhs on private placement basis.  These are
 redeemable at a premium of 5% in three equal instalments after six
 years from the date of allotment of debentures.
 
 1992
 
 - The new monocrotophos plant was commissioned at Santa Monica
 Works.
 The production activities at the Bhandup plant were suspended due to
 continued loss for the last 10 years.
 
 - The project to manufacture anti-oxidants at Goa were to be
 implemented in phases.  During the year, diazinon based formulation
 which would be useful as a soil insecticide as well as for control
 of
 important pests in rice, cotton and vegetable crop was proposed to
 be
 launched.
 
 1993
 
 - During the year Cibaca Gel toothpaste was introduced.  The
 Pharmaceutical division introduced Nitroderm-TTS which is used by
 angina patients.  The performance of agricultural division was
 affected
 due to reduced import duty on pesticides and intermediates and
 reduction in excise duty on intermediates.  This division was
 divided
 into Crop Protection and Animal Health division.
 
 - The Company entered into a joint venture agreement with Ciba-Geigy
 Ltd., Switzerland and Chong Kun Dang Corporation, South Korean to
 establish a joint venture company Ciba CKD Biochem Ltd to
 manufacture
 anti-Tuberculosis drug Rifampicin.  The plant was to be set up at
 Mahad, Maharashtra with an installed capacity of 125 tonnes per
 annum.
     
 1994
 
 - Protexin and ESB 3, the new products were introduced.
 
 - The new tinopal CBS-X plant was commissioned with a production
 capacity of 1000 tonnes per annum along with a state of the art
 chemical waste incinerator plant.
 
 1995 - The Company introduced three new products and two line
 extension.  The Combi-Pack, 4D, which contain 4 essential drugs viz.
 Isoniazid, Rifampicin, Pyrazinamide and Ethambutol and Ebutol were
 launched.  Besides these Regestrone HRT and PZA suspension were also
 introduced.
 
 - Effective from 29th March, Ciba CKD Biochem Ltd. became a
 subsidiary
 of the Company.  The shareholders of Cibi-Geigy AG and Sandoz AG
 approved for the merger of two companies to form a new company
 `Novartis'.  Novartis would hold a premier position in its core
 business - Pharmaceuticals, agribusiness and Nutrition.  It was also
 proposed to demerge the speciality chemicals business of Ciba.
   
 1996
 
 - The following new products were added during the year in the
 pharma
 division. (1) Lamisil(R) - for treatment of fungal skin and nail
 infections. (2) Leponex(R) - for schizopherenic patients non
 responsive
 to classical neuroleptics. (3) Lioresal - an anti-spastic muscle
 relaxant in treatment of spastic conditions. (4) Orfiz - an oral
 rehydration salt, a user friendly effervescent ORS tablet. (5)
 Parlodel(R) - for infertility and gynaecological disorders. (6)
 Voltaflam - a fast acting analgesic for acute painful conditions.
 
 - During the year, the Company proposed to close down its
 undertaking
 at Kandla that was set up to cater exclusively to the export
 business
 in USSR.
 
 - During December, approvals were reserved for restructuring
 business
 operations of the company by denerging.  Approval was received for
 subdivision of company's shares from existing Rs 100 per shares into
 10
 equity shares of Rs 10 each and for exchange of 15 Sandoz India Ltd.
 shares for 10 shares of Novartis India Ltd.
 
 - The allotment of shares took place: 1. For every one original
 shares
 of Rs. 100 each held in Hindustan Ciba-Greigy Ltd. on 4.11.1997,
 sharehodlers would received 5 shares of Rs 10 each in Ciba Geigy
 Speciality Chemicals (India) Ltd.  2. For every one sub-divided
 shares
 of 10 held in Hindustan Ciba-Geigy Ltd. on 4.11.1997 shareholders
 will
 secure 1 share of Rs 10 each in Novartis India Ltd. 3. For every 15
 shares held in Sandoz (India) Ltd. on 23.10.1997, shareholder will
 receive 10 shares of Rs 10 each in Novartis India Ltd.
 
 1997
 
 - The company introduced Topik, a speciality herbicide for wheat.
 While consolidating its presence in the metro markets, the company
 expanded its presence in additional towns and cities to extend its
 reach in the domestic market.
 
 - The joint venture, Indo-Swiss Chemicals Ltd, will market polyester
 and celluloid dyes to be manufactured initially by IDI at its Kalyan
 and Ranoli plants in Maharashtra and Gujarat.
 
 - Hindustan Ciba-Geigy has trimmed its labour force by 13 per cent
 and
 more workers are likely to accept the voluntary retirement scheme
 (VRS)
 offered by the company.
 
 - The merger of Sandoz India (SIL) with Hindustan Ciba Geigy (HCG)
 has
 taken a new turn even as the Indian affiliates of Ciba-Geigy and
 Sandoz, both based in Basle, Switzerland, have begun the integration
 process to form Novartis India.
 
 - Walden, a US private equity fund, is picking up an equity stake in
 Ciba-CKD Biochem, a joint venture between Novartis, Switzerland,
 Hindustan Ciba-Geigy and Korean fermentation major Chong Kun Dang
 (CKD).
 
 - Hindustan Ciba Geigy and Sandoz (India) which are on the verge of
 merging formally to form Novartis (India) are in moves to transfer
 their combined development team to Novartis Enterprises Private
 Limited
 (NEPL), a 100 per cent Indian subsidiary of Novartis AG, the
 Novartis
 parent company.
 
 1998
 
 - Novartis (India)'s pharmaceutical business is likely to get a
 bonus
 addition in November this year with the return to its portfolio of
 cough and cold preparation Triaminic.
 
 - The board of Novartis India has approved transfer of the company's
 29.22 lakh (9.17 per cent) equity shares held by Ciba India Pvt Ltd
 in
 favour of Novartis AG of Switzerland.
 
 1999
 
 - Novartis India Ltd is close to finalising its first acquisition in
 India.  The company, through its eyecare business, CibaVision, is
 buying an eyedrop brand called Clearine from Optrex Ltd, a part of
 the
 United Breweries group.
 
 2000
 
 - The Company has firmed up plans to spin off its agribusiness into
 a
 separate entity, Novartis Agribusiness India Pvt. Ltd.
 
 - The Company's shareholders are being offered one equity share of Rs
 5
 each in NAIPL for every one fully-paid equity share of Rs 5 held in
 Novartis India.
 
 - Novartis India, the Indian subsidiary of the Swiss pharma giant,
 has
 become a signatory to the Global Working Alliance on Tuberculosis
 drug
 development, paving way for its greater involvement in anti-TB drug
 research.
 
 - The Compay has launched Calcium Sandoz as an over-the-counter
 product
 in India in two flavours, American Ice Cream and Orange.
 
 2001
 
 
 - The P1 + rating assigned to the Rs 50-crore CP programme of
 Novartis
 India Ltd is reaffirmed.
 
 - Novartis India Ltd. together with Ciba Speciality Chemicals India
 Ltd. signed a letter of intent with Kingston Properties Private Ltd.
 for the sale of their rights and interests in their properties at
 Goregaon in Mumbai.
 
 2002
 
 - The Board of Directors of Novartis India Ltd announced changes in
 its composition effective November 01, 2002. Dr R Thompson who moves
 to a new assignment with Novartis USA, cases to be a Director. Mr R
 Sahani, CEO- Pharma will succeed Dr Thompson as Vice Chairman and
 Managing Director. Asha Mirchnandani Chief Financial Officer will be
 inducted on the Board as Executive Finance Director.
 
 2003
 
 -Novartis India Ltd has announced the appointment of  Anil Matai as
 the Chief Executive
 Officer, Pharmaceuticals.
 
 -Novartis India Ltd has unveiled Myfortic - an enteric-coated
 advanced formulation under
 the immunosuppresant category.
 
 -Novartis announced it has changed its import currency to US Dollar
 from swis Franc.
 
 -Completed formalities for transfer of its third plot of land
 situated at Goregaon, to Kingston Properties Private Ltd on receipt
 of consideration of Rs 171.07 million
 
 
 2004
 
 -Charak Pharma has inked an alliance with multinational pharma major
 Novartis India for the promotion of three animal healthcare products
 from the Charak stable.
 
 -The Switzerland-based Novartis Pharma AG has established a software
 development centre at Mumbai.
 
 -Novartis establishes third plant in Mumbai
 
 -Biocon's R&D subsidiary, Syngene International, has announced that
 it has entered into a contract research agreement with Novartis'
 research and development arm, the Novartis Institutes for Biomedical
 Research Inc
 
 -Novartis rolls out new spray 'Otrivin-O'
 
 2005
 
 -Novartis India members approve sell of Rifampicin bulk drug
 business, by Postal Ballot.
 
 -Patent application for blood cancer drug is within range says
 Novartis.
 
 -The 50:50 joint venture between Chiron Vaccines and Panacea would be
 benefited if Novartis finally picks up the balance equity in the
 US-based company. 
 
 
 2006
 
 -Hikal's Vice-Chairman and Managing Director Mr Jai Hiremath has been
 appointed as Director on the board of Novartis India Ltd.
 
 
 2007
 
 -Dr. P Jager has been appointed as Director and succeeds Dr.
 Schillinger as the Chairman of the Board of Directors.
 
 -Novartis India Ltd has given the following details regardind E-mail
 ID of the grievance redressal division / compliance officer:
 
 1. Mr. Hemang Maniar  Company Secretary & Head Investor Relations
 Email ID  hemang.maniar@novartis.com
 
 2. Ms. Marylou D'Souza  Legal & Secretarial Assistant
 Email ID  marylou.dsouza@novartis.com
 
 
 2010
 
 -Novartis announced that officials from the European Commission (EC)
 have approved its meningitis vaccine - Menveo.
 
 -Novartis bets on rural sales initiative ‘Arogya Parviar’ to double
 its reach in India.
 
 2011
 -Novartis India has recommended dividend of Rs. 10/- per equity share
 of Rs. 5 each.
 
 2012
 -Novartis India has recommended dividend Rs 10/- per equity share of
 Rs .5 each
 
 2013
 -Novartis India has recommended dividend Rs 10/- per equity share of
 Rs .5 each
 
 2014
 --Novartis India has recommended dividend Rs 10/- per equity share of
 Rs .5 each
 
 2016
 -Novartis is featured as one of the 2016 Top 100 Global Innovators
 -Novartis is proud to once again rank #2 in the FORTUNE World's Most
 Admired Companies Pharmaceuticals Industry list.
 -Novartis ranks third in 2016 Access to Medicine Index
 -Two Novartis products receive 2016 Prix Galien Foundation Awards
 -Novartis received an A- rating and is recognized among category
 leaders in healthcare in the 2016 CDP Climate Score. 
 
 2017
 -Novartis on FORTUNE's list of the World's Most Admired Companies
 2017.
 
 2018
 -Novartis ranks second in 2018 Access to Medicine Index.
 
 2019
 -Novartis recognized with Learning Strategy Innovation Award 2019.
 -Novartis makes the 2019 Top Employer list from Science Magazine.
 
 2020
 -Novartis launches Biome India, a digital innovation hub in
 Hyderabad.
 -Novartis receives bronze award for best People Development Program
 2020.
 
 2021
 -Novartis is recognized as a Global Top Employer for 2021. 
 -Novartis ranks second in 2021 Access to Medicine Index.